CAPLIPOINT2024-04-012024-06-30 CAPLIPOINT2024-04-012024-06-30in-bse-fin:OneOperatingExpenses01Member CAPLIPOINT2024-06-30 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524742 CAPLIPOINT NOTLISTED Caplin Point Laboratories Limited Equity 2024-04-01 2025-03-31 2024-08-07 2024-07-31 INR Crores First quarter 11:15:00 12:45:00 2024-08-07 2024-08-07 Not applicable Single segment Pharmaceutical Formualtions 2024-04-01 2024-06-30 Unaudited Standalone 1856400000.00 215000000.00 2071400000.00 363800000.00 161800000.00 78100000.00 108600000.00 200000.00 61800000.00 330300000.00 1104600000.00 966800000.00 0.00 966800000.00 245700000.00 -4300000.00 241400000.00 0.00 725400000.00 0.00 0.00 0.00 0.00 725400000.00 0.00 725400000.00 0.00 0.00 152000000.00 2 9.55 9.50 0.00 0.00 9.55 9.50 1) The above Standalone Results for quarter ended June 30, 2024 were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 7, 2024. 2) The Unaudited Standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ( the Act ) read with relevant rules issued thereunder ( Ind AS ) and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI ( Listing Obligations and Disclosure Requirments) Regulations, 2015. 3) The Company is engaged in the sole activity of carrying on the business of Pharmaceutical Formulations and therefore, has only one reportable segment in accordance with Ind AS 108 Operating Segments . Hence no separate segment reporting is applicable to the Company. 4) Other Income for the quarter ended June 30, 2024 includes Dividend of Rs. NIL as against Rs. 15.29 Crores for the quarter ended June 30, 2023, received from Caplin Point Far East Limited, Hong Kong (wholly owned subsidiary). 5) During the quarter ended June 30, 2024 the Company has alloted 68,550 equity shares of Rs. 2/- each under the Employees Stock Option Schemes and the total number of equity shares of the Company stands at 7,60,10,296 as at June 30, 2024. The Company had allotted NIL shares and 31,000 shares during the quarter ended March 31, 2024 and June 30, 2023 respectively. Other Expenses 330300000.00 0.00 0.00